Optimizing 211At production cross section by studying the rise of 210At cross section: First measurement using Linac SPIRAL2

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389005%3A_____%2F25%3A00639373" target="_blank" >RIV/61389005:_____/25:00639373 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S0969804325004063" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0969804325004063</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.apradiso.2025.112061" target="_blank" >10.1016/j.apradiso.2025.112061</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Optimizing 211At production cross section by studying the rise of 210At cross section: First measurement using Linac SPIRAL2

Popis výsledku v původním jazyce

Targeted Alpha Therapy (TAT) offers a promising approach to treat cancer, particularly micrometastases, by utilizing the short range and high linear energy transfer of alpha particles emitted by radionuclides. At-211 (half-life 7.2h) is one of the promising alpha emitters (only one alpha emitted during decay) that has been identified for nuclear medicine applications. It belongs to the halogen family and shares chemical properties with iodine, an element used for imaging (I-123, I-124 and I-131) and also widely used to treat thyroid cancer (I-131). This chemical similarity enables the use of Iodine as an analogue for biodistribution and dosimetry studies while using At-211 for treatment in a theranostic approach. In this study, an alpha beam accelerated by SPIRAL2, was used to produce At-211 via the reaction Bi-209(alpha, 2n)At-211 on the NFS beam line. The production cross section of At-211 increases with increasing alpha energy up to 31 MeV. However, above 28.6 MeV, the production of At-210 occurs via the Bi-209(alpha, 3n)At-210 reaction. At-210 decays to Po-210, a highly toxic alpha-emitting radionuclide with a half-life of 138.3 days which cannot be separated chemically. Therefore, it is crucial to have a thorough understanding of the rise in At-210 production to optimize the generation of At-211 while minimizing the production of At-210 To achieve this, Bi-209 targets were irradiated at various alpha beam energies between 28 to 31 MeV with high precision thanks to the characteristics of SPIRAL2 accelerator and At-210,At-211 cross sections were measured by using gamma-ray spectroscopy. The incident particle flux was monitored using an instrumented Faraday cup. This flux measurement combined with the number of detected gamma-rays allowed to determine the production cross sections of At-210,At-211 as a function of energy. The results are in good agreement with experimental values recommended by the International Atomic Energy Agency (IAEA) for At-211 and provide supplemental data for At-210 between 28.6 and 31 MeV. The data collected in this study will help optimize the energy range of interest for the production of At-211 and give At-211 its rightful place as a radionuclide for TAT.

Název v anglickém jazyce

Optimizing 211At production cross section by studying the rise of 210At cross section: First measurement using Linac SPIRAL2

Popis výsledku anglicky

Targeted Alpha Therapy (TAT) offers a promising approach to treat cancer, particularly micrometastases, by utilizing the short range and high linear energy transfer of alpha particles emitted by radionuclides. At-211 (half-life 7.2h) is one of the promising alpha emitters (only one alpha emitted during decay) that has been identified for nuclear medicine applications. It belongs to the halogen family and shares chemical properties with iodine, an element used for imaging (I-123, I-124 and I-131) and also widely used to treat thyroid cancer (I-131). This chemical similarity enables the use of Iodine as an analogue for biodistribution and dosimetry studies while using At-211 for treatment in a theranostic approach. In this study, an alpha beam accelerated by SPIRAL2, was used to produce At-211 via the reaction Bi-209(alpha, 2n)At-211 on the NFS beam line. The production cross section of At-211 increases with increasing alpha energy up to 31 MeV. However, above 28.6 MeV, the production of At-210 occurs via the Bi-209(alpha, 3n)At-210 reaction. At-210 decays to Po-210, a highly toxic alpha-emitting radionuclide with a half-life of 138.3 days which cannot be separated chemically. Therefore, it is crucial to have a thorough understanding of the rise in At-210 production to optimize the generation of At-211 while minimizing the production of At-210 To achieve this, Bi-209 targets were irradiated at various alpha beam energies between 28 to 31 MeV with high precision thanks to the characteristics of SPIRAL2 accelerator and At-210,At-211 cross sections were measured by using gamma-ray spectroscopy. The incident particle flux was monitored using an instrumented Faraday cup. This flux measurement combined with the number of detected gamma-rays allowed to determine the production cross sections of At-210,At-211 as a function of energy. The results are in good agreement with experimental values recommended by the International Atomic Energy Agency (IAEA) for At-211 and provide supplemental data for At-210 between 28.6 and 31 MeV. The data collected in this study will help optimize the energy range of interest for the production of At-211 and give At-211 its rightful place as a radionuclide for TAT.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

10304 - Nuclear physics

Projekt

<a href="/cs/project/LM2023071" target="_blank" >LM2023071: Système de Production d’Ions Radioactifs Accélérés en Ligne – účast České republiky</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Applied Radiation and Isotopes

ISSN

0969-8043

e-ISSN

1872-9800

Svazek periodika

225

Číslo periodika v rámci svazku

November

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

112061

Kód UT WoS článku

001552427900003

EID výsledku v databázi Scopus

2-s2.0-105012630229